Dadun Dadun cabecera universidad cabecera biblioteca
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Aterosclerosis e inflamación > DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista >

Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?
Authors: Rocha, E. (Eduardo)
Llorens, R. (Rafael)
Paramo, J.A. (José Antonio)
Arcas, R. (R.)
Cuesta, B. (Braulia)
Martin-Trenor, A. (Alejandro)
Keywords: Cardiopulmonary Bypass
Deamino Arginine Vasopressin/therapeutic use
Hemorrhage/prevention & control
Postoperative Complications/prevention & control
Issue Date: 1988
Publisher: Lippincott, Williams & Wilkins
Publisher version: http://circ.ahajournals.org/content/77/6/1319
ISSN: 1524-4539
Citation: Rocha E, Llorens R, Paramo JA, Arcas R, Cuesta B, Trenor AM. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988 Jun;77(6):1319-1323.
Abstract
It has been suggested that desmopressin acetate (DDAVP) administration reduces blood loss after cardiac surgery. We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery. Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded. Results showed no significant differences either in total blood loss per square meter (458 +/- 206 ml in the DDAVP group vs 536 +/- 304 ml in the placebo group) or in necessity for red cell transfusions (1642 +/- 705 ml in the DDAVP group vs 1574 +/- 645 ml in the placebo group) in the first 72 hr after surgery. Only intraoperative blood loss per square meter was significantly lower (p less than .02) in the DDAVP group (131 +/- 106 ml) as compared with the placebo group (193 +/- 137 ml). The prolongation of bleeding time and the decrease of factor VIII:C and factor VIII:von Willebrand factor 90 min after treatment were significantly lower (p less than .001) in the DDAVP group as compared with the placebo group. We conclude that the administration of DDAVP in patients placed on cardiopulmonary bypass during surgery does not reduce total blood loss and is only effective in reducing intraoperative bleeding.
Permanent link: http://hdl.handle.net/10171/22335
Appears in Collections:DA - CUN - Cirugía cardiaca - Artículos de revista
DA - CUN - Cardiología - Artículos de revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista

Files in This Item:
File:  Circulation1988_771319.pdf
Description: 
Size:  843,03 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.